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Abstract 
Unlike other currently available progestogens, drospirenone (DRSP) has a pharmacological profile, which 
closely mimics that of endogenous progesterone, most notably potent anti-aldosterone and anti-androgenic 
effects. Consequently, DRSP, when combined with 17β-estradiol (E2) as hormone replacement therapy (HRT), 
offsets E2-related water and sodium retention by blocking the mineralocorticoid receptor. This review evaluates 
the potential benefits offered by DRSP as the progestin component of HRT with respect to its anti-aldosterone 
activity, which translates into positive effects on body weight and blood pressure in clinical trials of continuous, 
combined E2/DRSP in post-menopausal women. In a 1 -year, large-scale, randomised, controlled trial, E2 1 
mg/DRSP 2 mg significantly decreased mean body weight by 1.2 kg versus baseline (P < 0.001), whereas 
patients receiving E2 1 mg gained weight. E2 1 mg/DRSP 2 mg also significantly lowered mean systolic blood 
pressure (SBP) by 9.0 mmHg from baseline (P < 0.05) versus 3.7 mmHg in the E2 1 mg group (P = 0.220) in a 
sub-group of hypertensive women. In addition, E2/DRSP was not associated with hyperkalemia (potassium ≥ 5.5 
meq/L) irrespective of concomitant use of ACE inhibitors, angiotensin II receptor antagonists or non-steroidal 
anti-inflammatory drugs, and co-morbid diabetes mellitus. In summary, as well as effectively treating climacteric 
symptoms, DRSP 2 mg combined with E2 1 mg has shown positive effects on body weight and blood pressure in 
clinical trials, most likely due to DRSP's anti-aldosterone properties. This combination may therefore offer an 
alternative therapeutic option with additional benefits beyond current HRT agents for symptomatic post-
menopausal women. 
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1. Introduction 
It is estimated that 47 million women per annum will be menopausal by 2030 [1], and approximately 80% of 
these women will experience transient or permanent symptoms, related to the loss of estrogens, during   the   
menopause   stages   [2].   The   transient menopausal symptoms can be vasomotor in origin, i.e. hot flushes, 
night sweats or palpitations, or psychological, such as insomnia. Permanent symptoms include urogenital 
atrophy and osteoporosis. 
For decades, estrogen, either alone or in combination with progestogens, has been the therapy of choice for the 
relief of menopausal symptoms, as well as for the long-term prevention of post-menopausal osteoporosis. The 
inclusion of a progestogen in continuous combined hormone replacement therapy (HRT) decreases the risks of 
endometrial hyperplasia and cancer associated with unopposed estrogen therapy, and this approach eliminates 
regular withdrawal bleeding [3,4]. Evidence-based guidelines strongly recommend the use of combined 
estrogen/progestin therapy in women with an intact uterus, using the lowest dose to relieve symptoms effectively 
and minimise side-effects [5-9]. However, the potential benefits of HRT on cardiovascular disease, blood 
pressure and weight gain remain controversial, and may depend on the specific regimen used. 
Post-menopausal women have a higher prevalence of hypertension than pre-menopausal women [10-12], and are 
consequently at an increased risk of cardiovascular disease. High blood pressure is a modifiable risk factor, as 
reductions can lower the incidence of stroke and coronary heart disease (CHD). Even lowering the blood 
pressure in pre-hypertensive individuals (systolic blood pressure [SBP] 120-139 mmHg or diastolic blood 
pressure [DBP] 80-89 mmHg) may have an added health benefit [13]. Treatment with conventional HRT 
appeared to have no significant effect on blood pressure in a number of studies [13-18]. The risk of hypertension 
was increased in current HRT users in the WHI study, although this may have been related in part to the older 
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patient cohort in this study (average 62 years) [12]. In some patients, blood pressure may increase due to the 
water- and sodium-retaining effects of the estrogen in HRT preparations, mediated via the renin-angiotensin-
aldosterone system (RAAS) [19]. 
Weight changes can occur independently of the menopause, although adverse weight changes in body fat 
distribution and composition are linked to hormonal changes [20]. It is widely perceived that HRT causes weight 
gain [21,22], although data from clinical trials examining weight gain is inconclusive, in some studies showing 
an increase in overall body weight [15,23-25] and others showing no significant effect [26-32]. It is possible that 
differences in measures of weight gain, physical activity of responders, HRT regimens (e.g. the use of 
micronized progesterone), may account for the differences observed in these trials. Some studies indicate that 
HRT may have positive effects on body fat distribution [25,28-32], for example, data from the Post-menopausal 
Estrogen/Progestin Interventions (PEPI) trial showed that HRT may reduce central adiposity [32], although the 
current evidence is inconclusive [26]. 
Nevertheless, weight gain is perceived as a side-effect and is commonly cited as a reason for not taking HRT 
[21,22,33,34]. The Norwegian Woman and Cancer (NOWAC) study, which sampled 4996 women (1024 HRT 
users that experienced side-effects were identified) aged 45-64 years, showed that 56.3% of women experiencing 
troublesome side-effects reported weight gain as a side-effect [33]. Similar findings were observed in another 
large-scale survey of 816 women (449 responders). This study showed that concerns about weight gain were 
associated with a significant risk (RR = 2.06) for discontinuing HRT [34]. In contrast to endogenous 
progesterone, the currently available synthetic progestogens lack anti-aldosterone activity. This may result in 
HRT-associated water retention and bloating as a consequence of estrogen activity on the RAAS, which could 
contribute to perceived weight gain. This highlights the need for progestogenic compounds that mimic the 
effects of endogenous progesterone on the RAAS. Drospirenone (DRSP) is a novel progestogen with aldosterone 
receptor antagonism (PARA). In contrast with most synthetic progestogens, DRSP displays a very similar 
pharmacological profile to endogenous progesterone [35-37]. Thus, DRSP exhibits anti-aldosterone and anti-
androgenic properties, but is devoid of any estrogenic, glucocorticoid or anti-glucocorticoid activity [35,36,38-
40]. In particular, the anti-aldosterone activity of DRSP provides the potential for positive effects on body 
weight and also on blood pressure due to counterbalancing estrogen-related water retention when used in an 
HRT preparation. Several studies have demonstrated the safety and efficacy of the continuous combined HRT, 
17β-estradiol (E2) 1 mg and DRSP 2 mg (Angeliq®, Scher-ing AG, Germany) for the treatment of climacteric 
symptoms and prevention of post-menopausal osteoporosis [41-43]. In this review, the function of the RAAS, 
and in particular the effects of estrogen and progesterone, on body weight and blood pressure are discussed. The 
potentially advantageous effects of E2 1 mg/DRSP 2 mg on body weight and blood pressure in post-menopausal 
women are also evaluated. Due to its unique potent anti-aldosterone activity, DRSP in combination with E2, 
could offer an alternative HRT with a favourable benefit/riskratio for post-menopausal women. 
2. The influence of estrogen and progesterone on the RAAS 
The RAAS plays a key role in the regulation of body fluids and blood pressure. If there is a sustained fall in 
blood pressure, the kidney releases renin, which converts angiotensinogen to angiotensin I (Fig. 1). This inactive 
peptide is subsequently converted by angiotensin-converting enzyme (ACE) to the pharmacologically active 
angiotensin II. Angiotensin II in turn stimulates aldosterone secretion, resulting in conservation of sodium and 
water, and elimination of potassium by the kidney [40,44]. In addition, angiotensin II is a potent vasoconstrictor, 
causing acute elevations in blood pressure. The most important function of the RAAS is to prevent excessive 
sodium loss and to regulate blood pressure. In addition, aldosterone may be implicated in the pathogenesis of 
renal and cardiovascular disease. 
The female sex hormones, estrogen and progesterone are both known to influence the RAAS. Endogenous and 
orally administered estrogens promote the synthesis of angiotensinogen, leading to increased plasma aldosterone 
levels via the RAAS [19,44]. The net physiological effect of unopposed estrogen is increased sodium and water 
retention, and decreased potassium retention. In the natural menstrual cycle, progesterone counteracts the 
endogenous estrogen-induced stimulation of the RAAS by competing with aldosterone at the mineralocorticoid 




Published in: Maturitas (2006), vol. 55, iss.4, pp. 297-307 
Status: Postprint (Author’s version) 
Fig. 1. Influence of estrogen and progesterone on the renin-angiotensin-aldosterone system. 
 
3. DRSP: a synthetic progestogen with added benefits 
Progestogenic activity is essential in HRT preparations to counteract the proliferative effects of estrogen on the 
uterine endometrium. However, endogenous progesterone has low oral bioavailability and a short plasma half-
life, rendering the hormone unsuitable for use in HRT preparations [45,46]. Although micronized progesterone is 
available for use in HRT, and data, for example, from the PEPI trial demonstrated that it is effective [18], most 
HRT combinations contain a synthetic progestogen, commonly derived from 19-nortestosterone (e.g. 
norethisterone acetate [NETA]) or 17α-hydroxyprogesterone (e.g. medroxyprogesterone acetate [MPA]) [46-48]. 
While all conventional progestogens exert progestogenic activity, they exhibit different patterns of binding at 
other steroid receptors and consequently display diverse biological activities (Table 1) [40,46-48], which also 
prevent meaningful extrapolation of the results for one progestogen to all progestogens as a class, or indeed to all 
HRT preparations. 
 
Table 1: Comparison of the biological activities of progesterone and drospirenone with other progestogens 
Progestogens Biological activities 
 
Progestogenic Androgenic Anti-androgenic Anti-aldosterone Glucocorticoid
Progesterone + - ± + - 
Drospirenone + - + + - 
Cyproterone acetate + - + - ± 
Dienogest + - + - - 
Levonorgestrel + ± - - - 
Medroxyprogesterone 
acetate 
+ ± - - ± 
Norethisterone + ± - - - 
Trimegestone + - ± ± - 
Norgestimate + ± - - - 
Clinically relevant activity (+); activity not clinically relevant (±); no activity (-). 
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None of the progestogens currently used in conventional HRT preparations has a similar pharmacologic profile 
to that of progesterone, most notably with regard to their lack of anti-mineralocorticoid activity (Table 1). They 
are, therefore, unable to adequately counterbalance the water- and sodium-retaining effects of the estrogenic 
component of combined HRT, which may contribute to increased blood pressure and weight gain in susceptible 
individuals. As such, there is clearly an unmet clinical need for new, well-tolerated progestogenic compounds 
with improved selectivitythat mimic the effects of endogenous progesterone [47]. 
DRSP (6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone), differs from conventional 
progestogens as it is derived from 17α-spironolactone, rather than progesterone, 19-nortestosterone or 19-
norprogesterone [46,47]. The novel chemical structure of DRSP underpins its unique receptor binding profile 
among synthetic progestogens. Moreover, its binding region and biological activities are closely akin to those of 
endogenous progesterone (Table 1) [35,36,40]. DRSP and progesterone both exhibit moderate binding affinity to 
progesterone receptors and high binding affinity to mineralocorticoid receptors (as antagonists) in the uterus and 
kidney [45]. Both DRSP and progesterone have considerable anti-mineralocorticoid activity in transactivation 
studies of hormone receptors [35,38]. The anti-androgenic potency of DRSP is reported to be 5-10 times greater 
than that of progesterone and one-third that of cyproterone acetate (CPA). This contrasts with the absence of 
anti-androgenic activity for MPA [40,45]. Neither DRSP nor natural progesterone display estrogenic, androgenic 
or glucocorticoid activity [44,45,47]. Unlike other progestogens, DRSP has anti-aldosterone activity. The 
binding affinity of DRSP at the mineralocorticoid receptor is 2.3- to 5-fold higher than that of aldosterone, 
whereas the affinity of MPA or NETA is only approximately 3% that of aldosterone, and neither display anti-
mineralocorticoid activity [45,47]. In spontaneously hypertensive rats, SBP and DBP were decreased or 
remained unchanged over 27 days of DRSP administration, whereas blood pressure increased with conventional 
progestogens, such as CPA [45]. In addition, DRSP has been shown to increase sodium excretion compared with 
placebo or CPA in menstruating women [44]. Like progesterone, DRSP therefore has the potential to counter the 
increase in sodium and water retention caused by estrogenic stimulation of the RAAS, which may otherwise 
result in increased plasma volume, water retention-related symptoms and raised blood pressure in susceptible 
individuals. Thus, in contrast with conventional progestogens, the unique PARA activity of DRSP may offer 
beneficial effects on blood pressure and body weight in post-menopausal women. The ratio of pro-gestogenic to 
anti-mineralocorticoid activity is similar for DRSP and progesterone [44], and DRSP is the only available 
progestogen that has significant anti-aldosterone activity at dose levels sufficient to oppose the effects of E2 on 
the endometrium. DRSP in combination with E2 has, therefore, been developed as a continuous combined HRT, 
as well as an oral contraceptive with ethinyl estradiol (EE). 
4. The effect of DRSP on blood pressure 
Hypertension, defined by the JNC VII guidelines [13] as stage 1: SBP 140-159 mmHg or DBP 90-99 mmHg; 
stage 2: SBP ≥ 160 mmHg or DBP ≥ 100 mmHg, is linked to cardiovascular disease [49-51], a leading cause of 
death in the western world [52]. In the Framingham Heart Study, a longitudinal 30-year survey, which examined 
data from normotensive and untreated hypertensive subjects, SBP increased linearly with age; if left untreated, 
elevated SBP can accelerate large artery stiffness, an independent determinant of cardiovascular risk [51]. 
Age-related conditions such as the menopause can also have an impact on blood pressure. In a random cross-
sectional survey of households where blood pressure was measured on-site, data from 278 premenopausal 
women and 184 post-menopausal women showed that the latter group was associated with a higher incidence of 
hypertension (≥140/90 mmHg), which was still evident after adjusting for age and body mass index (BMI) [10]. 
Although blood pressure measurements were home-based, these results may still be subject to the white-coat 
effect, which is more relevant in small samples. Another larger survey, which reviewed 15 longitudinal and 
cross-sectional studies, found that after adjusting for age and BMI, no significant correlation was found between 
menopause and blood pressure. However, this paper did not state whether these subjects were normotensive or 
hypertensive at baseline, or whether they were receiving HRT or anti-hypertensive therapy [53]. 
The link between post-menopausal estrogen deficiency, hypertension and subsequent risk of cardiovascular 
disease, therefore, remains somewhat unclear. A review of blood pressure changes in hypertensive post-
menopausal women receiving conventional HRT agents has revealed a variety of effects, although in general, 
risks of increased blood pressure during therapy were low [13-18,53]. A small, observational study of 226 
normotensive post-menopausal women showed that HRT users had a smaller increase in SBP than non-users 
over the 5-6 year follow-up (change in SBP: 8.9 mmHg versus 1.6 mmHg; P = 0.01) [17]. However, one cannot 
rule out the possibility of a natural ageing effect, such as that observed in the Framingham Heart Study [51], 
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given the absence of a control group or defined endpoints. A number of well-designed trials (see Table 2) have 
consistently demonstrated a significant blood pressure-lowering effect with DRSP plus E2 in postmenopausal 
women [43,54-56]. This is consistent with the potent anti-aldosterone activity of DRSP. In one study, 24 post-
menopausal hypertensive women treated with enalapril (baseline blood pressure: 139/82 mmHg) were 
randomised to treatment with E2 1 mg/DRSP 3mg once daily or placebo plus enalapril for 14 days. Blood 
pressure was measured by 24 h ambulatory monitoring. E2/DRSP significantly reduced 24 h mean (±S.E.) SBP 
by 9 mmHg (±1.4) and DBP by 5 mmHg (± 1.2) from baseline (both P < 0.05), whereas no change in blood 
pressure was observed in the placebo plus enalapril group [54]. These findings show that E2/DRSP has added 
benefits on blood pressure when used in combination with other anti-hypertensive agents. 
 
Table 2: Summary of trials demonstrating the blood pressure-lowering effects of DRSP 
Study Population Design BP definition(s) Outcomes 
Preston et al. 
[54] 
Post-menopausal 








24 h ambulatory BP 
(no HTN criteria 
used) 
Significant additive BP-
lowering effect of 
E2/DRSP (mean decrease 
from 139/80 to 130/75 
mmHg), consistent with 
anti-mineralocorticoid 
effect 
Preston et al. 
[55] 
Post-menopausal 
women with T2D        
(n = 82) or without 
T2D (n = 148) treated 





Changes in clinic BP 
(no definition of HTN 
but baseline BP was 
132/81 mmHg) 
Higher BP reductions for 
E2/DRSP than PLA (mean 
reduction in total group:      
-8.6/-5.8 to -3.7/-2.9 
mmHg; P < 0.01). No 
difference in hyperkalemia 
(K ≥ 5.5 meq/L) between 
treatment groups 
White et al. 
[56] 
Post-menopausal 
women with stage 1 
HTN (n = 213) 
treated with 





Stage 1 HTN defined 
as SBP 140-159 
and/or DBP 90-99 
mmHg. Endpoints 
were changes in clinic 
BP and 24 h 
ambulatory BP 
Mean clinic BP reductions 
for E2/DRSP vs. PLA were 
-14.1/-7.9and-7.1/-4.3 
mmHg (P< 0.0001). 
Significant reductions in 
mean 24 h SBP were also 
observed after treatment 
with E2/DRSP (P = 0.002) 



















The probability of 
hyperplasia was 0.060 for 
the E2 group compared 
with 0.007 for E2/DRSP 
2mg. Significant reduction 
in mean BP after treatment 
with E2/DRSP 2 mg vs. E2 
(-9.0/-5.7 mmHg vs. -3.7/     
-2.7 mmHg) 
BP, blood pressure; DBP, diastolic blood pressure; DRSP, drospirenone; E2, 17β-estradiol; ENA, enalapril maleate; HTN, hypertension; 
PLA, placebo; SBP, systolic blood pressure; T2D, Type 2 diabetes mellitus. 
 
In a larger study, 230 post-menopausal hypertensive women treated with anti-hypertensive therapy (baseline 
blood pressure: 132/80 mmHg) were randomised to treatment with E2 1 mg/DRSP 3 mg or placebo for 28 days 
[55]. The mean decrease in clinic SBP from baseline was greater for E2/DRSP than placebo (-9.62 ± 1.30 and -
2.78 ± 1.02 mmHg, respectively; P<0.001) (Fig. 2A). Corresponding values for DBP were -5.74 mmHg (±0.72) 
and -2.94 mmHg (±0.65), respectively (P<0.01) (Fig. 2B). A similar trend was observed in a sub-group of 
patients with type 2 diabetes mellitus. 
In post-menopausal women with untreated stage 1 hypertension (SBP 140-159 mmHg; DBP 90-99 mmHg), 
treatment with E2 1 mg/DRSP 3 mg decreased both clinic and 24 h ambulatory blood pressure compared with 
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placebo after 12 weeks of therapy [56]. The mean clinic blood pressure was decreased by 14.1/7.9 mmHg 
(SBP/DBP) from baseline in patients receiving E2/DRSP compared with only 7.1/4.3 mmHg in the placebo 
group (P< 0.0001). These findings show that the combination of E2 1 mg/DRSP 3 mg has a significant effect on 
blood pressure in untreated hypertensive patients and an additive effect in patients treated with anti-
hypertensives. The reductions observed in the placebo group of these trials are consistent with previous findings 
and were not due to any lifestyle interventions. The placebo effect is a well-recognised phenomenon in blood 
pressure trials, and is usually more evident with clinic measures than 24 h ambulatory monitoring [57]. In a long-
term trial, which evaluated the safety of E2 1 mg and four regimens of E2 1 mg/DRSP (0.5, 1, 2 or 3mg) in 1147 
post-menopausal women, the combination of E2/DRSP was effective in protecting against endometrial 
hyperplasia [43]. Secondary endpoints included, amongst others, blood pressure assessments. Based on a post 
hoc analysis in 102 hypertensive women (SBP ≥ 140 mmHg and/or DBP ≥ 90mmHg), there was a significant 
decrease in mean SBP from baseline in those receiving E2 1 mg/DRSP 2mg (-9.0mmHg; P = 0.011; n = 15) 
whereas the decrease from baseline was not significant with E2 monotherapy (-3.7 mmHg; P = 0.220; n = 15) 
after 13, 28-day treatment cycles. Similarly, the mean DBP change from baseline in the E2/DRSP group was -5.7 
mmHg (P< 0.001) compared with -2.7 mmHg in the E2 monotherapy group (P = 0.108), although inter-
treatment comparisons did not reach significance. While this study also demonstrated a beneficial effect of 
E2/DRSP on total cholesterol and low-density lipoprotein cholesterol, there was no actual assessment of 
cardiovascular endpoints such as stroke, CHD or myocardial infarction. Long-term studies are needed to address 
the effect of E2/DRSP on cardiovascular outcomes in order to determine whether the observed reduction of 
blood pressure has implications for these serious risks. 
 
Fig. 2. Mean (±S.E.) SBP (A) and DBP (B) in post-menopausal women receiving treatment with E2 1 mg/DRSP 
3 mg or placebo for 28 days. DBP, diastolic blood pressure; DRSP, drospirenone; E2, 17β-estradiol; SBP, 
systolic blood pressure [55]. 
 
 
Nevertheless, these findings show that E2/DRSP consistently lowers blood pressure, which is most likely related 
to the anti-aldosterone activity of DRSP; aldosterone blockade increases renal sodium excretion, potentially 
leading to a reduction in SBP and DBP. Concomitant with the increase in sodium excretion via the RAAS, 
aldosterone receptor antagonists may also increase serum potassium concentrations, particularly in susceptible 
individuals [19,37]. However, E2/DRSP has not been associated with hyperkalemia (potassium ≥ 5.5 meq/L), 
even in high-risk patients [43,55,56]. When compared with placebo, treatment with E2 1 mg/DRSP 3 mg did not 
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increase serum potassium concentrations or the incidence of hyperkalaemia, irrespective of concomitant use of 
ACE inhibitors, angiotensin II receptors antagonists or nonsteroidal anti-inflammatory drugs, and co-morbid 
diabetes mellitus [55]. In addition, there were no clinically or statistically significant changes in serum potassium 
concentrations in patients with mild renal impairment and normal renal function when treated with DRSP or 
placebo [55]. 
Overall, E2 1 mg/DRSP 2 or 3 mg lowered SBP by approximately 7-14 mmHg and DBP by approximately 5-8 
mmHg in hypertensive post-menopausal women in these trials. Although these changes may appear small, 
decreases in SBP of only 2-3 mmHg have previously been associated with improved cardiovascular outcomes 
[58-60]. Mean reductions in SBP and DBP of 10 and 4 mmHg, respectively, have been shown to decrease the 
risks of stroke and myocardial infarction by 30% and 23% [58]. There is also evidence to suggest that across the 
blood pressure range 115/75-185/115 mmHg, the risk of cardiovascular disease doubles with each increment of 
20/10 mmHg in individuals aged 40-70 years [61]. These findings underscore the importance of even small 
decreases in blood pressure, and concur with recommendations to lower blood pressure by lifestyle changes even 
in pre-hypertensive individuals (i.e. SBP 120-139 mmHg or DBP 80-89 mmHg), as they are twice as likely to 
develop hypertension than individuals with lower blood pressures [13]. As yet, however, there are no data 
indicating that E2 1 mg/DRSP 2 mg has a role in reducing the risk of stroke or CHD in post-menopausal women 
with elevated blood pressure. 
5. The effect of DRSP on body weight 
Although women tend to gain weight after the menopause, regardless of whether or not they are prescribed HRT, 
particular concern among patients about weight gain during HRT can deter initiation of treatment and cause poor 
compliance and/or early discontinuation among users [21,22,33,34]. For instance, one quarter of former HRT 
users aged 45-75 years cited weight gain as a reason to discontinue therapy in a European study of 8012 women 
[22]. 
As mentioned above, DRSP is a potent aldosterone antagonist that acts on the mineralocorticoid receptor to 
decrease sodium reabsorption and water retention. The potential benefits offered by this improved 
pharmacological profile of DRSP have translated into a positive effect on body weight in clinical trials of an oral 
contraceptive containing DRSP and EE [62-64] (see Table 3). Data from two large, randomised, comparative 
trials show that mean body weight remained significantly lower in women receiving the oral contraceptive EE 30 
µg/DRSP 3 mg than in women receiving EE 30 µg/desogestrel 150 µg over 13 or 26 cycles [63,64]. 
Similar findings have been shown when E2/DRSP is used as HRT in post-menopausal women [43]. In one trial 
(see Table 2), post-menopausal women receiving E2 1 mg/DRSP 2 mg experienced a small decrease in body 
weight, whereas women receiving E2 1 mg monotherapy tended to gain weight, even after the first treatment 
cycle (Fig. 3) [43]. At study end (cycle 13), the mean difference between treatments was 0.9 kg (P< 0.001), with 
women in the E2/DRSP group losing a mean of 1.2 kg versus baseline over the study period (P< 0.001). These 
results suggest that DRSP 2 mg, when used in a combined continuous HRT treatment with E2, has a body 
weight-lowering effect in post-menopausal women. This favourable effect likely reflects the unique ability of 
DRSP to counteract estrogen-related water and sodium retention, whereas conventional progestogens are devoid 
of such anti-mineralocorticoid activity. 
 
Fig. 3. Change in body weight (mean±S.E.) in post-menopausal women receiving HRT with E2 1 mg/DRSP 2 mg 
or E2 1 mg for 13 cycles. *P< 0.001 vs. E2 monotherapy. DRSP, drospirenone; E2, 17β-estradiol; HRT, 
hormone replacement therapy; SBP, systolic blood pressure [43]. 
 
Published in: Maturitas (2006), vol. 55, iss.4, pp. 297-307 
Status: Postprint (Author’s version) 
 
Table 3: Summary of trials showing the beneficial effects of DSP on weight 
Study Population Design Weight assessment Outcomes 
Oelkers et al. 
[62] 
Healthy women           
(n = 80), aged 18-34 





trial (6 treatment 
cycles) 
Body weight 
measured by women 
on home scales every 
second day 
(unclothed, fasting 
states). Mean weights 
during a cycle were 
used for calculations 
Body weight reductions 
ranging from 0.8 to 1.7 kg 
in the DRSP/EE groups 
compared with an increase 
in the control group of 0.7 
kg (P < 0.05; DRSP/EE 
groups vs. control) 
Foidart et al. 
[63] 
Healthy women (n = 
900), aged 18-35 









measured by women 




Mean weights during 




In the DRSP/EE group, the 
mean body weight 
remained below baseline  
(-0.11 to -0.68 kg). In the 
EE/desogestrel group, 
there was an increase after 
cycle 5 (range: +0.02 to 
+0.89 kg) 
Huber et al. 
[64] 
Healthy women 
(n = 2069), aged 18-
35 





study (13 treatment 
cycles) 
Body weight 
measured by women 
on home scales 
(unclothed, fasting 
states). Mean weights 
during a cycle were 
used for calculations 
Weight loss was 
significantly greater in the 
EE/DRSP group than 




DRSP has a pharmacodynamic profile that is more similar to that of endogenous progesterone than other 
currently available synthetic progestogens. When administered with E2 1 mg, DRSP 2 mg is an effective and 
well-tolerated HRT for the treatment of climacteric symptoms and prevention of post-menopausal osteoporosis. 
Due to the unique anti-aldosterone activity of DRSP, E2 1 mg/DRSP 2 mg also confers a positive effect on body 
weight and blood pressure in post-menopausal women. By avoiding estrogen-related side-effects such as 
bloating and weight gain, E2 1 mg/DRSP 2 mg may improve compliance with HRT, which is important in order 
to achieve maximum treatment benefits such as effective symptom relief and protection against osteoporosis. In 
addition, by reducing blood pressure in post-menopausal women, E2 1 mg/DRSP 2 mg may offer additional 
health benefits to women potentially at risk of later cardiovascular disease, although this has yet to be directly 
evaluated in clinical trials. In summary, the novel properties of DRSP, in combination with E2, provide an 
alternative therapeutic option with additional benefits beyond current HRT agents. 
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